109 related articles for article (PubMed ID: 2334275)
1. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
Spruss T; Gust R; Müller R; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
[TBL] [Abstract][Full Text] [Related]
2. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
Reile H; Spruss T; Müller R; Gust R; Bernhardt G; Schönenberger H; Engel J
Arch Pharm (Weinheim); 1990 May; 323(5):301-6. PubMed ID: 2383173
[TBL] [Abstract][Full Text] [Related]
3. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
4. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
[TBL] [Abstract][Full Text] [Related]
5. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
[TBL] [Abstract][Full Text] [Related]
6. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
[TBL] [Abstract][Full Text] [Related]
7. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
[TBL] [Abstract][Full Text] [Related]
8. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
9. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
Spruss T; Schertl S; Schneider MR; Gust R; Bauer K; Schönenberger H
J Cancer Res Clin Oncol; 1993; 119(12):707-16. PubMed ID: 8408183
[TBL] [Abstract][Full Text] [Related]
10. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
J Cancer Res Clin Oncol; 1992; 118(3):201-8. PubMed ID: 1548285
[TBL] [Abstract][Full Text] [Related]
11. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
Gust R
Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
[TBL] [Abstract][Full Text] [Related]
12. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
[TBL] [Abstract][Full Text] [Related]
13. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469
[TBL] [Abstract][Full Text] [Related]
14. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
15. [The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers].
Karl J; Schönenberger H
Arch Pharm (Weinheim); 1988 Jul; 321(7):405-10. PubMed ID: 3219056
[No Abstract] [Full Text] [Related]
16. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Gust R; Karl J; Faderl M; Schönenberger H
Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
[TBL] [Abstract][Full Text] [Related]
18. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
Gust R; Schönenberger H
Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
[TBL] [Abstract][Full Text] [Related]
19. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell line.
Reile H; Müller R; Gust R; Laske R; Krischke W; Bernhardt G; Spruss T; Jennerwein M; Engel J; Seeber S
Arch Pharm (Weinheim); 1990 Mar; 323(3):133-40. PubMed ID: 2344259
[TBL] [Abstract][Full Text] [Related]
20. Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
Gust R; Bernhardt G; Spruss T; Krauser R; Koch M; Schönenberger H; Bauer KH; Schertl S; Lu Z
Arch Pharm (Weinheim); 1995 Sep; 328(9):645-53. PubMed ID: 7487421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
